Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetic Study of DYANAVEL XR in Children 4-5 Years with ADHD
NCT03610464Phase 4Completed
- Sponsor
- Tris Pharma
- Start
- May 2018
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of amphetamine in attention deficit hyperactivity disorder (ADHD), sponsored by Tris Pharma. Started May 2018; status: completed.
02
Drugs
amphetamine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT03610464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03610464.